Drug intelligence / Profile preview

Lengzhu granule

Development stage: Unknown
Lead developer: Guangdong Provincial Hospital of Chinese Medicine Zhuhai Hospital
Administration: Oral

Overview

Lengzhu granule is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Chinese Medicine Zhuhai Hospital. It is currently being investigated in clinical trials for the treatment of coronary heart disease (CHD) and coronary artery disease (CAD) characterized by critical stenosis (50–70%). The therapy is administered as an adjunct to guideline-directed secondary prevention. The clinical evaluation focuses on its efficacy in reducing weekly angina attacks and the need for emergency medication, while its mechanism of action is being explored through the analysis of inflammatory biomarkers and single-cell sequencing to understand its impact on the immune microenvironment and plaque stability.

Other names: Lengzhu granule

Beyond the preview

Go deeper on Lengzhu granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lengzhu granule.

Explore the full profile